RRML - Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- April 2024 -
 
A comprehensive review of Prof... 21
Recomandarea comună EFLM-COLA... 12
Understanding the pathogenesis... 7
Monocyte to high-density lipop... 7
Understanding the key differen... 6
Anti-thyroid peroxidase (TPO) ... 6
Predictive value of expression... 5
Function of the S1P pathway in... 4
Romanian Review of Laboratory ... 3
Value of four-dimensional comp... 3

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 32(1)/2024 DOI:10.2478/rrlm-2024-0003
XML
TXT

Case series

Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests

Melen Brinza, Valentina Uscatescu, Mihai Hemcinschi, Elisabeta Chiriac, Georgiana Gherghe, Daniel Coriu

Correspondence should be addressed to: Melen Brinza

Abstract:

This study presents a transversal investigation that we performed at Fundeni hospital (Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A. Ten patients diagnosed with hemophilia A were closely monitored using clinical and laboratory resources during Emicizumab treatment, with an average of 12.8 months. Among these patients, six exhibited anti-factor VIII inhibitors, changing the medical strategy and adding complexity to their clinical profiles. A comprehensive approach was adopted to assess the coagulation status of patients under Emicizumab therapy. The study employed several key coagulation monitoring tools, including thrombin generation time (TGT) and thrombelastography (TEG). These methodologies generated valuable results in evaluating the patients’ coagulation profiles during the treatment regimen. Additionally, traditional coagulation assays were utilized to gain a profound understanding of the overall coagulation dynamics and to evaluate the therapeutic response. During prophylaxis with Emicizumab all patients experienced a reduced number of bleeding events. Moreover, a subset of these patients underwent major surgical procedures (orthopedic joint replacements, cholecystectomy) with successful outcomes. These findings underscore the potential of Emicizumab therapy as an effective option for hemophilia A patients, including those with inhibitors. Our research provides physicians several insights, offering a potential avenue for improved patients’ care and treatment strategies that translate in enhanced quality of life for hemophilia A patients undergoing Emicizumab therapy.

Keywords: hemophilia A, inhibitors, Emicizumab

Received: 1.11.2023
Accepted: 4.12.2023
Published: 4.1.2024

 
  PDF Download full text PDF
(1309 KB)
     
 
How to cite
Brinza M, Uscatescu V, Hemcinschi M, Chiriac E, Gherghe G, Coriu D. Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests . Rev Romana Med Lab. 2024;32(1):89-96. DOI:10.2478/rrlm-2024-0003